Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm: Nyrada, NOX’s Subsidiary Non-oncology Company, Announces Key Progress with its Cholesterol-lowering Drug Candidate (ASX:NOX)

NYX-330 designed as small molecule, oral PCSK9 inhibitor Passes initial critical pre-clinical tests of effectiveness Intended for use in combination with statin drugs to achieve substantial f...read more

Noxopharm Announces Veyonda Registered Trade Mark for NOX66 (ASX:NOX)

Sydney, 20 August 2018: Noxopharm (ASX:NOX) today announces that the trade mark, VeyondaTM, has been approved in Australia as part of a world-wide application. NOX66 is due to embark next year on its ...read more

Noxopharm Meets with US Advisory Board to Consider Interim NOX66 Radiotherapy Clinical Data (ASX:NOX)

DARRT-1 provides evidence of more abscopal responses Meeting of US Advisory Board in Philadelphia Sydney, 8 August 2018 : Noxopharm (ASX:NOX) today provides a shareholder update on the Company...read more

Release of DARRT-1 Preliminary Safety Data at Clinical Conference (ASX:NOX)

Noxopharm (ASX: NOX) today announces presentation of a poster concerning its DARRT-1 clinical study to the Annual Scientific Meeting of the Australia and New Zealand Urogenital and Prostate Cancer (AN...read more

Noxopharm Announces Pre-Clinical Data Confirms Radio-Enhancing Potential of NOX66 for Paediatric Brain Cancer (DIPG) (ASX:NOX)

Diffuse Intrinsic Pontine Glioma (DIPG); highly aggressive and poorly responsive brain cancer of children Idronoxil (NOX66) significantly enhances ability of radiotherapy to kill DIPG cells. S...read more

Viewing: 196 - 210 of 200 Previous | Next